A20 is a ubiquitin modifying enzyme that restricts NF-kB signals and protects cells against tumor necrosis factor (TNF)-induced programmed cell death. Given recent data linking A20 (TNFAIP3) with human B cell lymphomas and systemic lupus erythematosus (SLE), we have generated mice bearing a floxed allele of Tnfaip3 to interrogate A20's roles in regulating B cell functions. A20-deficient B cells are hyperresponsive to multiple stimuli and display exaggerated NF-kB responses to CD40-induced signals. Mice expressing absent or hypomorphic amounts of A20 in B cells possess elevated numbers of germinal center B cells, autoantibodies, and glomerular immunoglobulin deposits. A20-deficient B cells are resistant to Fas-mediated cell death, probably due to increased expression of NF-kB-dependent antiapoptotic proteins such as Bcl-x. These findings show that A20 can restrict B cell survival, whereas A20 protects other cells from TNF-induced cell death. Our studies demonstrate how reduced A20 expression predisposes to autoimmunity.
INTRODUCTION
Maintenance of B cell homeostasis requires proper intracellular integration of signals delivered from multiple surface receptors such as the B cell antigen receptor, Toll-like receptors (TLRs), B cell-activating factor (BAFF) receptor, and CD40, as well as intracellular cues. Failure to integrate pathways such as NF-kB signaling can lead to B cell deficiency, aberrant B cell activity, or even lymphoma. Aberrant B cell tolerance and selection can cause production of autoantibodies, formation of immune complexes (IC), and ultimately tissue damage and autoimmune disease (Fairhurst et al., 2006) .
Tnfaip3 encodes the A20 protein, a ubiquitin-modifying enzyme (Wertz et al., 2004; Boone et al., 2004) . A20 was initially identified as a TNF-induced molecule that restricts TNF induced signaling (Opipari et al., 1990) . Targeting of Tnfaip3 in mice revealed A20s critical anti-inflammatory functions, given that A20-deficient (Tnfaip3 À/À ) mice exhibit severe spontaneous multiorgan inflammation, cachexia, and perinatal death (Lee et al., 2000) . Epistasis experiments revealed that A20 restricts TLR and nucleosome-binding oligomerization domain (NOD) triggered NF-kB signaling, in addition to TNF-induced NF-kB and programmed cell death (PCD) signaling (Lee et al., 2000; Boone et al., 2004; Hitotsumatsu et al., 2008) . Thus, A20 restricts a number of innate immune signaling pathways in macrophages and fibroblasts. The severe systemic inflammation and cachexia caused by A20 deficiency is ameliorated in mice that also lack the TLR adaptor protein MyD88 . Radiation chimeras bearing Tnfaip3 À/À hematopoietic cells also develop spontaneous systemic inflammation, which is alleviated by depletion of commensal intestinal bacteria with antibiotics . Thus, A20 maintains immune homeostasis and restricts the potentially proinflammatory nature of basal MyD88-dependent signals.
In addition to the innate immune functions described above in macrophages and fibroblasts, A20 is also expressed in T and B cells (Sarma et al., 1995; Lee et al., 2000) . During T cell activation, A20 is recruited to the MALT-1-Bcl-10 scaffold complex, and is cleaved by the paracaspase MALT-1 (Coornaert et al., 2008) . A20 has also been reported to deubiquitinate MALT-1 to restrict TCR signals (Dü wel et al., 2009 ). A20 cleavage is also observed in B lymphoma cell lines in response to BCR stimulation (Coornaert et al., 2008) . Other clues that A20 may play important roles in adaptive lymphocytes derives from human genetic studies that implicate A20 (or TNFAIP3) as a susceptibility gene for systemic lupus erythematosus (SLE)-an autoimmune disease associated with aberrant B cell function-as well as studies showing that A20 is a tumor suppressor in B cell lymphomas (Graham et al., 2008; Musone et al., 2008; Compagno et al., 2009; Kato et al., 2009; Novak et al., 2009; Schmitz et al., 2009) . Nevertheless, the physiological roles of A20 in T and B cells are largely undefined.
B cells are regulated by BCR, TLR, BAFF, and CD40 signals. These signaling cascades share some of the same ubiquitindependent signaling molecules utilized by TNF and TLR ligands (e.g., TRAF2, TRAF6, IKKg) (Hayden and Ghosh, 2008) . Given A20's role in preventing inflammation, its genetic linkage to human B cell lymphomas and SLE, and the central role B cells play in SLE pathogenesis, we hypothesized that A20 may regulate B cell homeostasis and prevent autoimmunity. To determine the cell intrinsic functions of A20 in regulating B cells, we have generated mice lacking A20 specifically in these cells.
RESULTS

B-Lineage Deletion of A20 Perturbs Lymphoid Homeostasis
In order to analyze the cell intrinsic functions of A20 in B cells, we generated a targeting construct in which exon 2 of the Tnfaip3 gene was flanked by loxP sites, a ''floxed'' allele. The targeting construct was transfected into C57BL/6 ES cells and neomycin resistant clones were screened for the targeted allele (Figures 1A and 1B) . Transient transfection of Cre recombinase resulted in removal of the neomycin cassette to obtain the floxed Tnfaip3 allele ( Figures 1A and 1B) . ES clones were injected into albino C57BL/6 blastocysts, and the resultant chimeras were bred Tnfaip3 exon 2 / β-actin (normalized ratio) with albino C57BL/6 mice. Non-albino C57BL/6 progeny were screened for the presence of the floxed allele, Tnfaip3 fl ( Figure 1B (Rickert et al., 1997) . All mice described in this study were heterozygous for the CD19-Cre targeted allele (CD19-Cre +/À ) to control for potential nonspecific effects of Cre expression while maintaining CD19 expression. For simplicity, CD19-Cre +/À mice will subsequently be referred to as CD19-Cre mice. As has been found for other ''floxed'' alleles, Tnfaip3 fl/fl CD19-Cre mice had efficient and B cell-specific deletion of Tnfaip3 exon 2, as assessed by genomic polymerase chain reaction (PCR) and Southern blotting ( Figure 1C and data not shown). Flow cytometry-sorted immature and germinal center (GC) B cells, subsets represented in smaller proportions, were also nearly 100% deleted as measured by quantitative genomic PCR ( Figure 1D ). A20 protein is constitutively expressed in B cells and T cells ( Figure 1E and data not shown). Deletion of tnfaip3 exon 2 on both alleles (Tnfaip3 fl/fl CD19-Cre) led to complete loss of A20 protein in splenic B cells ( Figure 1E ). Note that deletion of one allele of tnfaip3 in Tnfaip3 fl/+ CD19-Cre mice causes hypomorphic ($50%) expression of A20 protein in B cells ( Figure 1E ). Tnfaip3 fl/fl CD19-Cre mice were obtained in Mendelian numbers and developed normally. Hence, these mice differed dramatically from mice lacking A20 in all cells or in all hematopoietic cells, both of which develop severe spontaneous inflammation and early lethality (Lee et al., 2000; Boone et al., 2004; Turer et al., 2008) . To begin to assess the roles of A20 in regulating B cells, we quantitated lymphoid populations from 5-to 7-weekold Figure 2C and Figure S1B ). As CD19 is expressed throughout B cell development, these results suggest that A20 is not required for early B cell differentiation.
The differences in peripheral lymphocyte populations described above persisted but were not further exaggerated in 6-month-old mice ( Figure S1C Figure 2E and Figure S1D ). Spontaneous T cell activation was not observed (data not shown). In Vitro Our prior work indicated that A20 restricts TNF-, TLR-, and NODinduced NF-kB signals as well as TNF-induced PCD in fibroblasts and macrophages (Lee et al., 2000; Boone et al., 2004; Hitotsumatsu et al., 2008; Turer et al., 2008) . B cells receive activation, proliferation, and survival signals from BCR, CD40 receptor, and other receptors (Skaug et al., 2009 Figure S1D ). Tnfaip3 fl/fl CD19-Cre B cells expressed higher Figure 3C ). To control for potential differences in B cell populations and to avoid potential caveats associated with developmental abnormalities, we sought to eliminate A20 expression in mature B cells after B cell development. Accordingly, we interbred Tnfaip3 
A20 Restricts NF-kB Activation Signals Downstream of CD40
A20 restricts cellular responses to TNF, TLR, and NOD2 ligands by restricting NF-kB signaling (Lee et al., 2000; Boone et al., 2004; Hitotsumatsu et al., 2008; Turer et al., 2008) . CD40 is a tumor necrosis factor receptor (TNFR) family member that triggers NF-kB signals and supports B cell activation and survival (Elgueta et al., 2009 SNPs near the human A20 (TNFAIP3) gene are independently associated with susceptibility to SLE (Graham et al., 2008; Musone et al., 2008 Robinson et al., 2002) . Antibodies to over 46 self-antigens were detected, including antibodies to nuclear antigens (e.g., single-stranded DNA, small ribonuclear proteins A and C, and Ku protein), glomerular antigens (e.g., vimentin, collagen X, proteogylcan, and aggrecan), and heat-shock proteins ( Figure 5A ). Importantly, the serum autoantibody profiles from Tnfaip3 fl/fl CD19-Cre and Tnfaip3 fl/+ CD19-Cre mice clustered well with each other and away from Tnfaip3 +/+ CD19-Cre mice ( Figure 5A ).
These autoantibodies were observed in both male and female mice and were observed in C57BL/6 inbred mice, a strain that is relatively resistant to SLE-like disease. Elispot analysis for anti-DNA indicate both an increase in the number and size of anti-DNA producing B cells in Tnfaip3 fl/fl CD19-Cre mice ( Figure 5B and data not shown). These findings indicate that A20 expression in B cells prevents spontaneous production of autoantibodies.
Autoantibodies can be deposited in glomeruli of kidneys of SLE patients and ultimately cause glomerulonephritis. To determine whether serum autoantibodies in Tnfaip3 fl/fl CD19-Cre and
Tnfaip3
fl/+ CD19-Cre mice lead to glomerular Ig deposits, we examined kidneys from 6-month-old mice by histology and immunofluorescence. Although kidney sections appeared histologically normal, IgM deposits were observed in the kidneys of both Tnfaip3 fl/fl CD19-Cre and Tnfaip3 fl/+ CD19-Cre mice ( Figure 5C ). IgG deposits were more prominent in Tnfaip3 fl/+ CD19-Cre mice ( Figure 5C ).
In addition to autoantibody-producing B cells ''escaping'' from negative selection, activation of innate immune cells and type I interferon (IFN I) secretion may be key factors contributing to autoantibody production and the pathogenesis of SLE (Fairhurst et al., 2006; Shlomchik, 2008) . CpG triggers B cell activation and production of type I interferons (IFNs), and increases class switching to pathogenic autoantibody isotypes (Ehlers et al., 2006 Figure 5D and data not shown).
Taken together, these findings indicate that A20 expression in B cells prevents autoimmunity. Figure 6B ). This finding is particularly surprising given our prior observation that A20-deficient fibroblasts are more susceptible to TNF-induced PCD than normal cells (Lee et al., 2000) . Thus, A20 supports Fas-mediated PCD in B cells and inhibits TNFR-induced PCD in fibroblasts.
To understand why A20-deficient B cells are resistant to Fas mediated PCD, we hypothesized that increased NF-kB signaling in these cells might lead to increased expression of antiapoptotic proteins such as Bcl-x. After stimulation with agonist anti-CD40 in vitro, Bcl-x mRNA expression increased within 1 hr and rose to a higher amount in Figure 6C ). CD40 triggered induction of Bcl-x mRNA was blocked by the NF-kB inhibitor, NEMO-binding domain (NBD) peptide, but not by control peptide ( Figure 6C ). Hence, NF-kB signaling appears directly required for induced Bcl-x mRNA Figure 6D ). Taken together, these findings indicate that A20 restricts the survival of activated B cells by limiting the NF-kB-dependent transcription of Bcl-x mRNA and the subsequent production of Bcl-x protein. They also provide a potential mechanism by which A20 deficient B cells are resistant to negative selection in germinal centers.
DISCUSSION
The generation and characterization of mice lacking A20 specifically in B cells, Tnfaip3 fl/fl CD19-Cre mice, has allowed us to unveil several functions for A20. We have discovered that B cell-specific expression of A20 restricts CD40 and BCR responses, terminates CD40-triggered NF-kB signals, restricts B cell survival, and prevents autoimmunity. These studies provide unique molecular insights into B cell homeostasis, human SLE and B cell lymphomas. Tnfaip3 fl/fl CD19-Cre mice are largely healthy, in marked contrast to mice lacking A20 expression in all cells or in all hematopoietic cells. This observation is consistent with our prior suggestion that the cachexia, myeloid dysregulation, and perinatal lethality observed in globally A20-deficient mice is largely due to myeloid cell dysfunction. Although Tnfaip3 fl/fl CD19-Cre mice contained mild expansion of T cell numbers, these perturbations are probably not due to aberrant A20 deletion as judged by our molecular analyses and by the published literature for this Cre strain (Rickert et al., 1997; Schmidt-Supprian and Rajewsky, 2007) . Rather, these mice express increased quantities of splenic IL-4 mRNA (data not shown), and Tnfaip3 fl/fl CD19-Cre B cells produced more IL-6 and expressed higher amounts of costimulatory molecules upon stimulation. Thus, T cell expansion may be due to antigen-independent bystander effects induced by B cell-derived cytokines and/or costimulatory molecules, as has been observed in other settings of B cell hyperresponsiveness (Hö mig-Hö lzel et al., 2008; Hao et al., 2008 ). Our findings demonstrate that A20 performs important functions in adaptive immune cells in addition to previously described functions in innate immune cells (Lee et al., 2000; Boone et al., 2004; Hitotsumatsu et al., 2008 ). A20's roles in restricting CD40-and BCR-triggered NF-kB signals add to the spectrum of signaling cascades regulated by this ubiquitin modifying enzyme. NF-kB signaling is important for regulating B cell homeostasis (Sen, 2006; Siebenlist et al., 2005) . The phenotypes of our mice lacking A20 expression in B cells reveal the importance of tightly regulating basal NF-kB signals in these cells.
B cell-specific loss of A20 expression leads to increased numbers of autoantibody-producing cells. B cells undergo several stages of negative selection to eliminate autoreactive cells both in the bone marrow and in peripheral lymphoid organs ( Jacobi and Diamond, 2005; Shlomchik, 2008; Yurasov and Nussenzweig, 2007; von Boehmer and Melchers, 2010) . In the bone marrow, immature B cells are selected as a consequence of BCR and BAFF signals and intracellular cell survival factors. In the periphery, selection occurs during GC maturation. Germinal centers are sites where B cells undergo expansion, immunoglobulin class switching, somatic hypermutation, and affinity maturation (Klein and Dalla-Favera, 2008 ). B cells with low affinity for antigen or reactivity for self-antigens are negatively selected within GCs (Shlomchik, 2008) . Deletion of autoreactive B cells helps prevent autoimmunity, and defective GC selection of autoreactive B cells has been observed in human SLE patients (Cappione et al., 2005) . Fas (CD95) is highly expressed on GC B cells (Watanabe et al., 1995) . Although the role of Fas-mediated PCD in GC selection has been controversial (Smith et al., 1995; Takahashi et al., 2001; Mizuno et al., 2003; Hao et al., 2008) , Fas mediated PCD likely plays an important role in eliminating autoreactive B cells (Rathmell et al., 1995; Fukuyama et al., 2002; William et al., 2002) . Thus, the accumulation of GC B cells in Tnfaip3 fl/+ CD19-Cre and Tnfaip3 fl/fl CD19-Cre mice may be due to the increased resistance of A20-deficient B cells to physiological PCD, leading to the escape of autoreactive B cells.
How might A20 deficiency in B cells render them resistant to PCD? One possibility stems from the observation that NF-kBdependent proteins protect B cells against PCD. Indeed, both canonical and noncanonical NF-kB signaling downstream of BCR, CD40, BAFF, and TLR receptors are thought to promote B cell survival as well as proliferation and activation (Siebenlist et al., 2005; Sen, 2006; Hö mig-Hö lzel et al., 2008) . NF-kB has been suggested to be necessary for mediating BCR-induced resistance to Fas-mediated PCD (Mizuno et al., 2003; Schram and Rothstein, 2003) . Our studies indicate that A20 directly restricts canonical NF-kB signals and suggest that these signals may lead to elevated noncanonical NF-kB signals. These increased NF-kB signals lead to increased expression of antiapoptotic proteins such as Bcl-2 and Bcl-x. Deregulated expression of these proteins has been shown to cause altered GC B cell selection (Grillot et al., 1996; Takahashi et al., 1999) . Hence, increased expression of Bcl-x and/or other NF-kB-dependent proteins may provide a molecular underpinning for increased numbers of GC B cells in Tnfaip3 fl/fl CD19-Cre mice.
Heterozygous Tnfaip3 fl/+ CD19-Cre mice contain similarly increased numbers of GC B cells and autoantibodies as homozygous Tnfaip3 fl/fl CD19-Cre mice at young ages (i.e., 5-7 weeks old), suggesting that a high threshold of A20 expression must be maintained for properly selecting (or deleting) these cells. Reduced A20 expression in other cell types leads to increased production of NF-kB-dependent gene products, so endogenous amounts of A20 protein appear to be limiting (A.M., unpublished data). Reduced (rather than absent) quantities of A20 expression or hypomorphic A20 proteins may also link A20 (TNFAIP3) susceptibility SNPs with SLE in human patients (Musone et al., 2008) . Thus, mice expressing reduced amounts of A20 may prove to be highly relevant models of human autoimmune diseases. Although reduced A20 expression in B cells leads to accumulation of GC B cells and IgG autoantibodies, absent A20 expression also causes accumulation of immature B cells and IgM in Tnfaip3 fl/fl CD19-Cre mice and progressive activation of B cells with age. Hence, a lower amount of A20 is necessary to preserve selection of immature B cells and to restrict spontaneous B cell activation than the amount required for proper GC selection. As IgM autoantibodies may be protective against IgG-mediated autoimmune disease, higher IgM amounts in homozygous Tnfaip3 fl/fl CD19-Cre mice may reduce the degree of autoimmune disease observed in these mice (Witte, 2008) . A20 amounts are dynamically regulated, largely in response to NFkB signals (Krikos et al., 1992) . Thus, A20 expression amounts appear to be finely tuned to regulate NF-kB signaling and survival of distinct subsets of B cells. Our experiments indicate that A20 expression in B cells regulates GC B cell selection as well as B cell activation, thereby regulating key aspects of B cell tolerance. It is remarkable that B cell-specific deletion of A20 alone is sufficient for autoimmunity in C57BL/6 mice. The appearance of IgG deposits suggests that abnormal B cells are sufficient for at least the initial stages of the autoimmunity and are part of the continuum to full-blown disease. Hence, lupus-prone Tnfaip3 fl/fl
CD19-Cre and
Tnfaip3
fl/+ CD19-Cre mice as well as genetic derivatives of these mice should be useful models for understanding human SLE.
Heterozygous Tnfaip3 fl/+ CD19-Cre mice may be particularly relevant, as reduced, rather than absent A20 expression may characterize this human condition.
Recent studies have shown that somatic loss of A20 in B cells causes several types of Hodgkin, non-Hodgkin, and marginal zone B cell lymphomas in humans (Kato et al., 2009; Compagno et al., 2009; Schmitz et al., 2009; Novak et al., 2009) . Our findings that A20-deficient B cells express high amounts of Bcl-x and are resistant to Fas-mediated PCD provide molecular insights into how A20 functions as a tumor suppressor in B cells. Remarkably, A20 is a proapoptotic protein in B cells even though it restricts TNF-induced apoptosis in fibroblasts and hepatocytes (Lee et al., 2000; Arvelo et al., 2002) . Hence, it is critical to analyze A20's physiological functions in cell type-specific contexts. Future studies testing the potential of A20 deficiency to collaborate with other B cell oncogenes may reveal the spectrum of A20's tumor suppressor functions in B cells.
In conclusion, we have demonstrated functions for A20 in regulating B cell responses, including the restriction of CD40-induced NF-kB signals. These cell-autonomous functions are critical for B cell homeostasis and the prevention of autoreactive B cells and autoimmunity. In addition to unveiling new molecular mechanisms of B cell homeostasis, these studies provide critical insights into the pathogenesis of human SLE and B cell lymphomas. 
Cell Preparation and Analyses
Single-cell suspensions were prepared and incubated with the designated conjugated antibodies (all from BD Biosciences, except anti-CD5 and anti-CD93 [AA4.1], eBioscience), and live cells (DAPI À ) were analyzed by flow cytometry (LSRII, BD Biosciences) with FlowJo software (Tree Star). BMDMs were prepared as previously described . For in vitro assays, B cells were isolated by negative depletion with TCRb, Mac-1, NK1.1 and Ter119 biotinylated antibodies (BD Biosciences) bound to streptavidin coated magnetic beads (M-280 Dynabeads, Invitrogen). Cells were stimulated with anti-CD40 (HM40-3, BD Biosciences) at 1 mg/ml, anti-m chain (Jackson Immunoresearch) at 2 mg/ml, IL-4 (Peprotech) at 10 ng/ml, and LPS (Sigma) at 1 mg/ml. For in vitro deletion of tnfaip3 exon 2 from GT-Rosa Cre B cells, cells were treated with 4-OH-T (2.5 nM) for the first 12 hr of stimulation. For NF-kB inhibition, control peptide or NBD Peptide (Calbiochem) was added at 0.5 mM 1 hr prior to stimulation with agonist CD40 antibody.
Mouse Immunizations
For in vivo antigen responses, 6-to 8-week-old mice were injected intraperitoneally (i.p.) and bled on the indicated days. Mice were injected with 50 mg NP-KLH (Biosearch Technologies) mixed 1:1 with Imject Alum (Thermo Scientific). For CpG treatment, 8-week-old mice were injected i.p., every other day for 2 weeks, with 40 mg CpG ODN 2395 (tcgtcgttttcggcgcgcgccg) with phosphorothioate bases (Invitrogen). Serum was collected before treatment, and 6 weeks after treatment. All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco.
Immunoglobulin and AFC Determination
Quantities of serum and supernatant immunoglobulins (total Ig, IgM, IgG1, IgG2c, IgG2b, IgG3, and IgA) were determined by isotype specific ELISA (Southern Biotechnology). NP (4-Hydroxy-3-nitrophenylacetyl) -specific antibody titers were determined by ELISA with plates coated with NP 23 -BSA (Biosearch Technologies). dsDNA-specific antibody titers were determined by ELISA with plates coated with Hind III (New England Biolabs) digested pUC19 in 0.1M Tris, overnight at room temperature. Cytokines amounts were measured by ELISA as recommended by the manufacturer (BD Biosciences). Elispot was performed by incubating enriched B cells on plates coated with dsDNA as above. After overnight incubation, plates were washed and incubated with alkaline phosphatase (AP) conjugated anti-IgM (Southern Biotech) and subsequently developed with BCIP substrate (Sigma) dissolved into alkaline phosphatase buffer (0.1M Tris, 0.1 M NaCl, and 5 mM MgCl 2 ) and 0.6% LMP Agarose (Sigma).
Autoantigen arrays were printed and processed as previously described. Arrays were probed with goat antibody specific for mouse Ig (Jackson Immunoresearch). Detailed protocols and lists of antigens have been published and are available online at http://utzlab.stanford.edu/protocols (Robinson et al., 2002) . Significance analysis of microarrays (SAM) was applied to the data for identification of antigens with statistically significant differences in array reactivity between mutant and wild-type mice (Tusher et al., 2001 ).
Histology and Immunohistochemistry
Kidneys and spleens were fixed in 10% formalin. Sections and H&E stain were performed by the UCSF VAMC Pathology Core. For immunohistochemistry, kidneys were embedded in Tissue-Tek OCT compound and snap frozen in methyl-butane with dry ice. Tissue sections were then stained with IgM-FITC or IgG-FITC (Jackson Immunoresearch) or with IgG2c-FITC or IgG2b-FITC (Bethyl Laborotories).
Cell Signaling Assays
Enriched B cells were stimulated as indicated in the figures and lysed in 0.1% NP-40 (Calbiochem) lysis buffer, and nuclei were spun down so that cytoplasmic lysates were produced. Lysates were cleared by centrifugation at 14,000 g for 20 min at 4 C, supernatants were removed, heated in Laemmli buffer and run on SDS-PAGE (Novex System, Invitrogen). Immunoblots were probed for A20 , actin (JLA20, Calbiochem), phosphoIkBa, IkBa, phospho-Erk, Erk, phospho-NF-kB2 p100 and NF-kB2 p100/p52 (Cell Signaling), and Bcl-x (Transduction Biotechnologies).
Fas-Induced Cell Death Assay
Fas-induced cell death assays were performed as described (Watanabe et al., 1995; Wang et al., 1996) . In brief, enriched B cells were plated with agonist anti-CD40 (1 mg/ml) for 60 hr. Agonist anti-CD95 (Fas) was added to the cultures at the indicated doses for the last 12 hr. Cells were harvested and stained for flow cytometry with Annexin-V (BD Biosciences) and DAPI.
Real-Time PCR Assays
For quantitation of genomic Tnfaip3 exon 2, DNA was prepared with the DNeasy Kit (QIAGEN), after which qPCR was performed with SYBR Green (QIAGEN). Primers for exon 2 of Tnfaip3 were the following: 
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